Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
New MGA Analysis of the Adalimumab Biosimilars Market in the United States

New MGA Analysis of the Adalimumab Biosimilars Market in the United States

Feb 21, 2023 | Analysis, Press Releases

The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit

Dec 8, 2022 | Analysis

A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit.

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

Jul 14, 2022 | Analysis

MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.” 

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

May 26, 2022 | Analysis

MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.”

  • Analysis (42)
  • Books (3)
  • Commentary (4)
  • Events (16)
  • Interviews (55)
  • News (54)
  • Op-Eds (82)
  • Press Releases (4)
  • Testimony (20)
  • Regulatory Uncertainty for ESOPs
    New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee OwnershipOctober 2, 2023
  • PBMs in US Drug Pricing Debate
    MGA Releases White Paper on Role of PBMs in US Drug Pricing DebateSeptember 26, 2023
  • Unintended Consequences of Limiting PBMsSeptember 26, 2023
  • Importance of Prescription Drug Rebates
    ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the MediaAugust 11, 2023
  • Congress takes on PBMs
    1 big thing: Congress takes on PBMsAugust 9, 2023
  • Here comes Humira competition
    Here comes Humira competition July 20, 2023
  • Humira Competitors Don’t Guarantee
    Humira Competitors Don’t Guarantee Lower Patient Drug CostsJuly 19, 2023
  • The State of Biosimilars
    The State of Biosimilars: What to WatchJuly 18, 2023
  • Importance of Prescription Drug Rebates
    ‘The Price of Business’: Discussing the Latest Inflation ReportJuly 12, 2023
  • Brill discusses adalimumab market
    Alex Brill Interviewed on the Future of the Adalimumab Market June 28, 2023
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact